Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to 14.05%.

  • Burning Rock Biotech's EBITDA Margin rose 169000.0% to 14.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 21.61%, marking a year-over-year increase of 630000.0%. This contributed to the annual value of 66.53% for FY2024, which is 543200.0% up from last year.
  • As of Q3 2025, Burning Rock Biotech's EBITDA Margin stood at 14.05%, which was up 169000.0% from 6.69% recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's EBITDA Margin ranged from a high of 6.69% in Q2 2025 and a low of 195.13% during Q1 2022
  • Over the past 5 years, Burning Rock Biotech's median EBITDA Margin value was 133.96% (recorded in 2023), while the average stood at 110.69%.
  • Per our database at Business Quant, Burning Rock Biotech's EBITDA Margin crashed by -1189000bps in 2021 and then surged by 1077400bps in 2024.
  • Quarter analysis of 5 years shows Burning Rock Biotech's EBITDA Margin stood at 187.22% in 2021, then rose by 17bps to 156.21% in 2022, then increased by 13bps to 136.47% in 2023, then soared by 56bps to 59.74% in 2024, then skyrocketed by 76bps to 14.05% in 2025.
  • Its last three reported values are 14.05% in Q3 2025, 6.69% for Q2 2025, and 10.21% during Q1 2025.